Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940314 | 0.90 | FFAR1 (0.47) | FFAR1FFAR4SCN9ASCN3A | |
| SCHEMBL23927781 | 0.90 | FFAR1 (0.47) | FFAR1FFAR4SCN9ASCN3A | |
| SCHEMBL29423955 | 0.87 | FFAR1 (0.45) | FFAR1FFAR4CYP11B1CYP11B2 | |
| SCHEMBL29423951 | 0.84 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL29423900 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4PPARGPPARASCN3A | |
| SCHEMBL29423916 | 0.81 | FFAR1 (0.42) | FFAR1SCN9APPARG | |
| SCHEMBL15474005 | 0.80 | FFAR1 (0.52) | FFAR1FFAR4CYP11B1CYP11B2 | |
| SCHEMBL15471457 | 0.79 | FFAR1 (0.51) | FFAR1CYP11B1CYP11B2 | |
| SCHEMBL15473999 | 0.79 | FFAR1 (0.50) | FFAR1CYP11B1CYP11B2 | |
| SCHEMBL29423905 | 0.78 | FFAR1 (0.42) | FFAR1SCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |